Free tool
FAERS Monitor: Monistat 3
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020827 or its brand name (Monistat 3, Miconazole Nitrate). Reports on generic versions are filed under their own applications.
Reports
1,906
Serious
792
42% of reports
Hospitalization
331
Death reported
87
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vulvovaginal burning sensation424
- drug ineffective193
- vulvovaginal pain184
- vulvovaginal pruritus147
- vaginal haemorrhage113
- condition aggravated97
- vulvovaginal discomfort96
- pain77
- burning sensation72
- pruritus71
- off label use64
- drug interaction60
- abdominal pain59
- hypersensitivity55
- application site pain48
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 15 |
| 2006 | 21 |
| 2007 | 12 |
| 2008 | 38 |
| 2009 | 57 |
| 2010 | 37 |
| 2011 | 50 |
| 2012 | 80 |
| 2013 | 25 |
| 2014 | 30 |
| 2015 | 31 |
| 2016 | 105 |
| 2017 | 82 |
| 2018 | 125 |
| 2019 | 69 |
| 2020 | 116 |
| 2021 | 149 |
| 2022 | 171 |
| 2023 | 119 |
| 2024 | 160 |
| 2025 | 196 |
| 2026 | 198 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,253 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal burning sensationSignal | 424 | 823.6 | 754.4 | 323,527 |
| vulvovaginal painSignal | 184 | 438.2 | 380.8 | 76,794 |
| vulvovaginal pruritusSignal | 147 | 329.8 | 281.7 | 46,484 |
| vulvovaginal discomfortSignal | 96 | 245.0 | 201.1 | 22,588 |
| vaginal haemorrhageSignal | 113 | 28.8 | 24.1 | 3,003 |
| application site painSignal | 48 | 24.1 | 18.2 | 1,038 |
| burning sensationSignal | 72 | 11.3 | 9.0 | 670 |
| drug interactionSignal | 60 | 4.2 | 3.3 | 143 |
| condition aggravatedSignal | 97 | 3.5 | 2.9 | 175 |
| hypersensitivitySignal | 55 | 3.3 | 2.5 | 85 |
| abdominal painSignal | 59 | 2.8 | 2.2 | 67 |
| pruritusSignal | 71 | 2.0 | 1.6 | 37 |
| drug ineffective | 193 | 1.6 | 1.4 | 48 |
| pain | 77 | 1.4 | 1.1 | 8 |
| off label use | 64 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.